Q: Im looking for advice on how to deal with my almost-6-year-olds exceedingly snarky attitude. I know that eye-rolling, talking back, etc., are fairly age-appropriate, but, as our day-care provider put it, shes the sassiest little girl shes ever worked with in her decades as a preschool teacher. I was similar as a child, and my parents told me repeatedly that my attitude stunk and that I was unpleasant to be around. It wasnt until I was older and realized how many friendships had ended because of my attitude that I was able to make a change. What can I do for my daughter? I have no idea whether this have attitude, lose friends, learn from mistake process is inevitable. On the one hand, I want her to be a little sassy, unafraid to speak her mind and not polite to a fault. On the other hand, how do I get her to see that this level of attitude may alienate her? I dont want to change her. I just want her to understand the value of a filter to temper how she comes across.

A: There are a number of red flags in this question, and I want to address them so that we can clarify the real issue. I am not being critical of you; rather, I want to highlight a few concerns so that we can identify what you can change in your parenting life.

First, eye-rolling, talking back, etc., are not age-appropriate behaviors for your daughter. Although we sometimes see this in children of many ages, constant snark and sass are not appropriate. This is a sign of deeper frustration. I want to steer you away from the little girls are just sassy way of thinking. It is the equivalent of saying boys will be boys when little boys are violent, and I know we can look deeper here.

Second, sassiness and snark are not genetic. I know it is easy to see yourself in your child, but sassiness is not passed down through genes. Am I saying that I dont see generations of strong-willed women, one after another? Of course not. But this is more nurture than nature. If you look at temperament scales, outgoing parents can have outgoing children, and shy parents can have shy children. But sassiness? There is no sassiness temperament. Sassiness is a sign of something else.

[Our 6-year-old has a fun, comfortable life. Why isnt she grateful?]

Third, it can be fairly normal for children to be rude at home while acting like angels at school, but your daughter is being called the sassiest little girl in day care from a provider who has decades of experience. What is the day-care provider doing about this? Is everyone shrugging their shoulders like, Well, shes just completely obnoxious, and theres nothing we can do about it. I am concerned that there are lots of labels being put on your daughter but no help being offered.

Fourth, you are identifying with your daughter in a way that is preventing you from helping her. It seems clear from your note that you had a tough time when you were younger and paid for it. This suffering does not have to be your daughters fate, and you dont have to either go nuclear or just let her sort it out on her own. Shes almost 6 and needs some strong guidance, so lets get to it.

Regular and chronic sassiness and disrespect are a sign of deep discouragement and defensiveness in a child. Lets say youre married and dont feel like your spouse is listening to you and your opinions. You feel shut out, dismissed and rejected. Your impulses could go a couple of ways, depending on your alarm instincts. If youre like me, you are going to fight. You are going to confront, get mean and attack. Others retreat. They shut down, walk away and seek to avoid this pain. But the fighters? They will push, and then they will shut people out. So if your spouse asks you for your opinion and you have felt down and out for a long time, your heart will say: Oh, heck no. I dont trust this at all. And you very well may give an eye-roll and a smart comment. Your heart is saying: You have been too hurt by this dismissal. I am going to protect you, even if it hurts the situation.

Your daughter is defending herself against listening to people and taking instruction because her heart and mind have decided that is not safe. There is a little wall around your daughters heart, and every time she even perceives that she is being attacked or bullied, the wall springs up, protects her and becomes stronger.

She is not necessarily doing anything wrong. For very sensitive children, its a natural defense against vulnerability. They are taking in so much sensory information and experiencing so many emotions that their minds and hearts become overwhelmed and say, Thats enough, and the children shut down.

First bit of homework: Stop calling your daughter sassy. Rename this emotion discouragement, and you will instantly begin to have more empathy for her. Labeling her as sassy doesnt help her mature. It keeps her boxed in as a pain in the bottom, and you both dont need that. Also, dont take all this eye-rolling personally. Does this mean that you like it or dont care? Of course not. Just remember that she is reacting to emotions of alarm and protection. She is not consciously trying to hurt you.

Second bit of homework: You cannot demand respect or kindness from her. It will make her even more frustrated. The way into her heart is through small doses of connection in non-threatening ways. For instance, is there a project you can work on together where she can find her voice and have agency over something? Dedicate only a bit of time to this every day, because too much one-on-one time will discourage her.

When she is sassy, relabel it as frustration right then and there. When she rolls her eyes, say, I see how frustrated you are with this decision. The more we can put names to her feelings, the more we can move her from sassy, snarky and bad to frustrated, discouraged and sad. These words will help you communicate with her about her true feelings.

Place some boundaries on her behavior. For instance, let her know that if she has a play date and acts this way, her friend will leave immediately. Make good on this the first time it happens. She will throw a tantrum of epic proportions, but as long as you dont punish her and put your relationship on the line, she will adapt. Dont draw boundaries everywhere (you will never stop fighting), but choose your lines thoughtfully and stick with your rule.

Finally, take a listening stance whenever possible. When she says something rude, say: Sounds like you really dont like that idea. I wonder what you are really thinking. Then pause. See what happens.

I will warn you that if your daughter has been acting this way for a long time, things wont work themselves out overnight. Children who push boundaries can be frustrating, so do what you need to do to keep your feelings in check as you do this heavy emotional lifting. But this can get better! Good luck.

Send questions about parenting to meghan@mlparentcoach.com.

Continue reading here:
Don't blame genetics for daughter's sassy demeanor. It's more nurture than nature. - Washington Post

Myriad Genetics, Inc.MYGN introduced riskScore under its myRisk Hereditary Cancer testing portfolio. The launch is aimed at solidifying the company's footprint in the rapidly growing hereditary cancer testing market. Based in Salt Lake City, UT, this leading molecular diagnostics and personalized medicines providerintends to make riskScore a precision medical tool for patients who use myRisk to get their tests done.

Notably, riskScore helps determine a woman's risk of developing breast cancer by combining genetic markers throughout the genome with the patient's family and clinical history.

Per management, this highly advanced prediction tool will also aid 90% of the patients with negative results for heredity cancer genes to derive proper conclusions.

In June, the company had presented encouraging data from a 2,000-patient clinical study with myRisk Hereditary Cancer testsat the American Society of Clinical Oncology (ASCO). The results highlighted the importance of the multi-gene panel testing for advancement of the hereditary cancer-risk evaluation platform. Per management, around 50% of the identified mutations were found in patients who did not comply with the testing guidelines. The study also found 34% of identified mutations in unexpected genes.

Myriad Genetics has been riding high on strength in the Heriditary Cancer testing space. In the last reported quarter, the company saw 6% year-over-year rise in Heriditary Cancer testing volumes, marking the third consecutive quarter of sequential growth.

Per a report by DPI Research on Medium, the breast cancer screening market in the United States is expected to reach a value of roughly $5.8 billion by 2022. Moreover, per an article by BrestCancer.Org, approximately 252,710 new cases of invasive breast cancer in women are likely to be diagnosed in the United States in 2017. They also project 63,410 new cases of non-invasive (in situ) breast cancer this year as well.

We believe an ageing population, rising awareness and expenditure in healthcare will continue to drive growth in the breast cancer screening market. However, this market is dominated by many well established players, Quest Diagnostics DGX being the most prominent one. In this space, Quest Diagnostics' Quest Vantage services help in the discovery of genetic variants related to the hereditary risk of 15 types of cancer, including breast, colorectal, pancreatic and renal.

Moreover, Myriad Genetics has been gaining investor confidence on consistently positive results. Over the past three months, the company's share price has outperformed the broader industry . The stock has gained 41%, higher than the broader industry's 12.6%. The company has also outperformed the 0.7% gain of the S&P 500 market over the same time frame.

Zacks Rank & Key Picks

Myriad Genetics carries a Zacks Rank #3 (Hold). A couple of better-ranked medical stocks are Edwards Lifesciences Corporation EW and Lantheus Holdings, Inc. LNTH . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 23.6% over the last six months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 30.2% over the last six months.

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without . More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really takes off.

S ee Stocks Now>>

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report

Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report

Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

See the article here:
Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite - Nasdaq

Newswise Again and again, its the rare among humans that help the rest of us. The exploration of human genetics is revealing new targets to combat heart disease among atypical variants. Mutations in genes that play a role in heart health are the inspiration for a cluster of new heart drugs. One of the best examples is the discovery of mutations in the PCSK9 gene. People with a variant of this enzyme have lower LDL levels (the bad cholesterol), which protects them against heart disease. The discovery led to the development of a new class of heart medications called PCSK9 inhibitors, which markedly reduce LDLs in people with out-of-control levels. At the annual meeting of the American College of Cardiology this past spring, researchers announced that these inhibitors reduced the combined risk of having a heart attack or stroke or dying from cardiovascular disease in high-risk patients by 15 percent.

Other investigators are extending the hunt for how these mutations affect risk to tackle other aspects of heart disease. For instance, people whose LDL levels are under control but have elevated triglycerides are still at risk for continued plaque buildup in their arteries. Individuals with mutations in genes that play a role in breaking down excess triglycerides in the blood are pointing geneticists to other ways to protect at-risk people. In fact, a recent New York Times article describes a trio of papers about these rare mutations in people with extremely low triglyceride levels. These studies followed a previous discovery that mutations in the APOC3 gene naturally cause extra-low triglyceride levels. Normally, the APOC3 gene instructs cells to make a molecule that inhibits the breakdown of triglycerides.

Daniel Rader, MD, chair of Genetics, and other Penn Medicine researchers, were coauthors on these recent human-genetic studies, as well as others earlier this year. All of the APOC3 variants are associated with low triglycerides, independent of LDL cholesterol levels. The findings represent a potential new and separate line of attack for lowering risk of heart disease.

If we could harness the protective aspects of these APOC3 variants to develop therapies that act similarly and lower triglycerides and heart disease risk, these could theoretically work alongside existing LDL-lowering drugs, Rader said.

He adds that its hard to say how many people have normal LDL but high triglycerides, but its clearly in the millions, not a small number. There are currently no proven therapies to further reduce risk in these individuals.

Studies of large groups of people with one disabled APOC3 gene have led to its characterization as a highly validated therapeutic target for reducing the risk of heart disease. In other words, these studies have shown that diminished function of APOC3 is consistently associated with lower triglyceride levels and reduced risk of heart disease in large populations across the world.

One new therapy targeting APOC3 is showing promise: an antisense oligonucleotide, which is essentially a small stretch of DNA that binds to the APOC3 RNAs to block the protein from being made. This antisense drugs, which is administered subcutaneously, has shown substantial reductions in triglyceride levels in humans, further proving that disabling the APOC3 protein works the way the researchers had hoped.

Therapeutic antibodies engineered molecules that bind to specific proteins on cell surfaces are an established way to inhibit or inactivate circulating proteins to treat disease, and Rader notes that creating antibodies to the AP0C3 protein may be another useful strategy. The recently approved antibody to the PCSK9 protein is one example of this approach in action for lowering LDL and reducing heart disease.

In the newest human genetics study from the Rader lab, the team studied people with one disabled copy of the APOC3 gene (found by searching the over 50,000 participants in the Penn Medicine Biobank) and mice expressing the same human variant and showed that both had markedly reduced levels of APOC3 protein and triglycerides in their blood. From this, they showed that an antibody targeting the APOC3 protein could accelerate the breakdown of triglyceride-rich lipoproteins in the mice, mimicking the effects of this natural mutation.

The APOC3 protein antibody was developed by the biotech firm Argenx in collaboration with Staten Biotechnology. Rader says this approach is currently being developed by Staten and could be in clinical trials within the next two years.

This new translational genetics study, Rader said, adds one more check in the win column for the value of studying rare human genetic variants to inform our understanding of common conditions.

SEE ORIGINAL STUDY

Excerpt from:
Human Genetics Studies Reveal New Targets to Reduce Heart Disease - Newswise (press release)

Submitted by The Whale Museum

Learn about South resident killer whale genetics at a free lecture at 6:30 p.m., Thursday, Sept. 14 at The Whale Museum.

Dr. Lance Barrett-Lennard, head of the Cetacean Research Program at the Vancouver Aquarium, will discuss genetic comparisons of orca populations in the North East Pacific. This presentation is part of the museums Summer Lecture Series.

Barrett-Lennards research shows that at least nine genetically discrete overlapping populations of killer whales inhabit the northeastern Pacific Ocean. It also shows that resident killer whales avoid inbreeding through an elaborate clan-based mating system. His findings are the reason the Southern resident killer whales are listed as an endangered population through the Committee on the Status of Endangered Wildlife in Canada. More recently, he co-chaired a panel that produced a comprehensive recovery strategy for resident killer whales.

Barrett-Lennard has performed studies on behavioral and population biology of killer whales in British Columbia, Washington, Alaska since 1984, as well as species in Norway, Spain and the sub-Antarctic. He uses DNA analysis to better understand population divisions, dispersal patterns and mating systems. In addition to killer whales, Lance is involved in research on baleen whales, dolphins, sea otters, and belugas.

The Summer Lecture Series are given by local or visiting experts in their field, who share their recent research projects, stories and experiences. Each lecture is free and held at The Whale Museum. Donations are appreciated.

For more information, call 360-378-4710 ext.30 or visit http://www.whalemuseum.org.

View post:
Top researcher gives free lecture on orca genetics - Journal of the San Juan Islands

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 at 2:05 p.m. EDT. The presentation will be webcast live and available for replay from the Investors section of the Seattle Genetics website at http://www.seattlegenetics.com.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The companys industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS (brentuximab vedotin), the companys lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs and is commercially available globally in 67 countries for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing enfortumab vedotin, an ADC in a planned pivotal trial for metastatic urothelial cancer, in collaboration with Astellas and tisotumab vedotin, an ADC in a phase 1/2 trial for solid tumors, in collaboration with Genmab. Headquartered in Bothell, Washington and with European and international operations in Zug, Switzerland, Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer. More information can be found at http://www.seattlegenetics.com.

The rest is here:
Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference - Business Wire (press release)